Artiva Biotherapeutics, Inc.

NasdaqGM:ARTV Stock Report

Market Cap: US$286.9m

Artiva Biotherapeutics Past Earnings Performance

Past criteria checks 0/6

Artiva Biotherapeutics's earnings have been declining at an average annual rate of -9.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 58.4% per year.

Key information

-9.4%

Earnings growth rate

4.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate58.4%
Return on equity-30.5%
Net Margin-2,355.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22

Revenue & Expenses Breakdown

How Artiva Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:ARTV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243-611548
30 Jun 2429-331348
31 Mar 2433-261447
31 Dec 2333-291450
31 Mar 235-632149
31 Dec 225-592144
31 Mar 223-411430
31 Dec 212-721342
30 Sep 211-661038
31 Dec 200-18414

Quality Earnings: ARTV is currently unprofitable.

Growing Profit Margin: ARTV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARTV is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.

Accelerating Growth: Unable to compare ARTV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ARTV has a negative Return on Equity (-30.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies